Diloxanide furoate dosage

Talwar et al. reported a simultaneous spectrophotometric determination of diloxanide furoate and metronidazole in dosage forms [15]. The drug substances were extracted from tablets with methanol, and the extract diluted with 0.01 M sodium hydroxide. The absorbance of the solution was measured at 247 and 320 nm against 0.01 M sodium hydroxide, and the concentration of each individual drug was calculated by the Vierordt method. Drug recoveries were in the range of 99 to 100%, and the method was satisfactorily applied to the analysis of commercial samples. 

Sethi et al. reported the assay by two methods of diloxanide furoate and tinidazole in combined dosage forms, [16]. One of these was a dualwavelength spectrophotometric method, and the other a difference spectrophotometric method. In the first method, the absorbance of sample solution was measured at 259 and 311 nm. The concentration of tinidazole was calculated from absorbance at 311 nm, and the concentration of diloxanide furoate was calculated with the use of a given equation. In the second method, the absorbance of an aqueous solution of... 

Das and Haider described a simultaneous spectrophotometrie method for the analysis of binary dosage form mixtures of diloxanide furoate with metronidazole or with tinidazole [19], Powdered tablets or suspension, equivalent to 50 mg of the drug substances, were dissolved in 50 mL of dimethylformamide with shaking. After 15 minutes, the solution was diluted to 100 mL with water and filtered. A 1 mL portion of the filtrate was diluted to 50 mL with water, and the absorbance of the resulting solution measured at 320 and 262 nm for metronidazole and diloxanide furoate simultaneously. Alternatively, readings were taken at 318 and 262 nm for the simultaneous determination of tinidazole and diloxanide furoate. Recoveries were reported to be quantitative. 

Sadana and Gaonkar described a simultaneous derivative spectroscopic method for the determination of diloxanide furoate and tinidazole in pharmaceutical dosage forms [26]. Drugs were powdered and dissolved in methanol, and the solution set aside for 30 minutes with frequent shaking. After filtration, the filtrate and washings were diluted with methanol. A suspension equivalent to 150 mg of diloxanide furoate was extracted with chloroform. The filtered extract was evaporated to dryness, and the... 

Sadana and Gaonkar have simultaneously determined diloxanide furoate and tinidazole in pharmaceutical dosage form by gas liquid chromatography [37]. Powdered tablets or suspension formulations were dissolved in chloroform, the solution filtered, and then diluted to 25 mL with chloroform. The solution also contained metronidazole as an internal standard. A 600 nL aliquot was analyzed on a stainless steel column (1 m X 3.2 mm) containing 3% of OV-17 on Chlorosorb W-UP (100-120 mesh). The GC system was operated at 200°C, using nitrogen as the carrier gas (45 mL/min). Flame ionization detection was used to observe the analytes. 

The separation and estimation of diloxanide furoate and metronidazole in solid dosage forms was reported by Bhoir et al., using packed column supercritical fluid chromatography [38], A JASCO Cig colunm (10 pm particle size, 25 cm x 4 mm) was used at 40°C, with an injection volume of 20 pL. The mobile phase consisted of 26% methanol in CO2 (flow rate of 2 mL/min), and operated at a pressure of 17.6 MPa. When detected on the basis of its ultraviolet absorbance at 230 nm, the retention time for the drug was 1.6 minutes. The linear region of the calibration graph was reported to be 20-70 pg/mL. 

Ray used high performance liquid chromatography to estimate diloxanide furoate and tinidazole in single and combined dosage forms [39], Tablets were dissolved in the mobile phase, and 20 pL was injected on to a stainless steel column (30 cm x 3.9 mm) of p-Bondapak Cig. 8 3 methanol 0.05 M phosphoric acid (pH 3) was used as the mobile phase (flow rate of 2.5 mL/min), and detection was on the basis of the UV absorption at 254 nm. 

El-gizawy reported the analysis of diloxanide furoate in its dosage forms by a HPLC method [40]. Furazol tablets containing 200 mg of metronidazole and 250 mg of diloxanide furoate were treated with 50 mL of methanol, sonicated for 10 minutes, and diluted to 100 mL with methanol. A portion of the resulting solution was centrifuged, and a 20 pL portion of the clear supernatant solution diluted to 10 mL with the mobile phase. This process yielded a final analyte concentration equivalent to 5 pg/mL. 20 pL aliquots of the solution were annualized by HPLC using a stainless steel column (10 cm x 4.6 mm) packed with Cyclobond I. The mobile phase consisted of 13 7 0.05 M phosphate buffer (pH 7) methanol (flow rate of 1 mL/min), and detection was performed at 254 nm. 

Rao et al. reported a high performance liquid chromatographic method to determine diloxanide furoate and metronidazole in single and in combined dosage forms [41]. A 30 mg equivalent of diloxanide furoate and 25 mg of metronidazole (either as the bulk drug substances or in powdered tablets) was dissolved in methanol, amidopyrine added as the internal standard, and the mixture analyzed by HPLC at room temperature. The analytical column (30 cm x 3.9 mm) consisted of p-Bondapak Cig, with 9 9 1 1 methanol water 0.05 M KH2PO4 0.05 M NaH2P04 as the mobile phase. The flow rate was 1 mL/min), and detection was performed at 254 nm. 

---

See also in sourсe #XX -- [ ]

---